Ariceum Therapeutics Announces Planned Retirement of CMO

BERLIN, 14 October 2022 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, today announces that Chief Medical Officer, Alexander “Sandy” McEwan, M.D., will retire from the Company as Chief Medical Officer on the 15th of October 2022. Germo Gericke, M.D., former Chief Medical Officer of Advanced Accelerator Applications (AAA), a Novartis company, will join the Company on a consultancy basis as part of a planned transition. Sandy will work closely with Germo and the leadership team to ensure a smooth transition and will remain available in a part-time advisory role.

Eduardo Bravo, Chairman of Ariceum Therapeutics, said: “On behalf of the Board, I would like to thank Sandy for his experience and leadership in helping to build Ariceum from start up through to launch, and for his significant contributions in the development of our clinical lead asset, satoreotide, which will be used as a ‘theranostic’ for both the diagnosis and treatment of tumours expressing the SST2 receptor. We wish him all the best for his pending retirement. We are delighted to welcome Germo who will work closely with the leadership team in the coming months on a consultancy basis as we continue to build and progress our technology platform and advance satoreotide.”

Sandy McEwan, M.D., Chief Medical Officer of Ariceum Therapeutics, commented: “I am very proud of all we have achieved in the past year. I would like to thank all my colleagues in the Ariceum team for all their contributions and for the progress we have made in a short time. I wish them well in their ongoing efforts to discover and develop innovative new radiopharmaceutical treatments for patients suffering from hard-to-treat cancers, and for their families.”


For further information, please contact:

Ariceum Therapeutics
Manfred Rüdiger, CEO

Optimum Strategic Communications
Mary Clark, Charlotte Hepburne-Scott, Zoe Bolt
Tel: +44 (0) 20 3882 9621

Notes to Editors

About Ariceum Therapeutics

Ariceum Therapeutics (Ariceum) is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of ‘Marie Curie’ whose discovery of radium and polonium have been huge contributions to finding treatments for cancer. Ariceum’s lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (“satoreotide”) is an antagonist of the somatostatin type 2 receptor (SST2) which is overexpressed in neuroendocrine tumours (NETs), some aggressive cancers such as small cell lung cancer (SCLC) and the childhood cancer, neuroblastoma, all of which have few treatment options and poor prognoses. Satoreotide is being developed as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of these tumours.

Ariceum Therapeutics, launched in 2021, acquired all rights from Ipsen. Ariceum is headquartered in Berlin, with operations in Germany and activities currently across Europe, North America and Australia.

Ariceum is led by a highly experienced management team and supported by specialist investors including EQT Life Sciences (formerly LSP), HealthCap and Pureos Bioventures. For further information, please visit